Exicure, Inc. (Nasdaq: XCUR) announced on November 4, 2026, that it has entered into an Intellectual Property, Asset and License Assignment Agreement with GPCRT Inc., a corporation organized under the laws of the Republic of Korea. Under the agreement, GPCRT will acquire the assets related to the GPC-100 (burixafor) program from Exicure and its wholly owned subsidiary, GPCR Therapeutics USA Inc.

The transaction involves the sale of Exicure’s rights under its License and Collaboration Agreement with GPCR Therapeutics, Inc., dated January 19, 2025. The assets include associated contracts, intellectual property, clinical and regulatory data, physical materials, and equipment used in the GPC-100 program. GPCR USA will remain a wholly owned subsidiary of Exicure following the closing of the deal.

The aggregate purchase price for the assets is KRW 6,500,000,000 (approximately US$4.8 million). The payment structure is as follows: KRW 500,000,000 has already been paid by GPCRT and will be credited against the total; an interim payment of KRW 2,000,000,000 is due on or before November 16, 2026; and a final payment of KRW 4,000,000,000 is due at the closing.

Under the terms of the agreement, GPCRT will assume the obligations under the License and Collaboration Agreement, including future milestone and royalty payments, as well as obligations under assigned program contracts. The Purchaser will also bear the costs of the GPC-100 program incurred on or after September 1, 2026. Conversely, Exicure and GPCR USA will retain all other liabilities, including those incurred before September 1, 2026.

The closing of the transaction is subject to customary conditions, including the approval of the boards of directors of Exicure, GPCR USA, and GPCRT; receipt of required regulatory approvals and third-party consents; a waiver and release from GPCR Therapeutics, Inc.; and any necessary stockholder approval. Exicure noted that there is no assurance the transaction will be completed on the anticipated timetable or at all.

The GPC-100 program is being evaluated in combination with propranolol for stem cell mobilization in patients with multiple myeloma. GPCR USA completed a Phase 2 clinical trial of GPC-100 in January 2026. The sale of these assets is part of Exicure’s ongoing evaluation of strategic alternatives intended to maximize stockholder value and strengthen the Company’s financial position.